Chest Medicine (all articles)
Guideline Synopsis | Therapy for mild to moderate asthma.
22 Jul, 2022 | 11:48h | UTCTherapy for Mild to Moderate Asthma – JAMA (free for a limited period)
Original Guideline: 2022 GINA Report, Global Strategy for Asthma Management and Prevention
M-A | Risk factors for asthma exacerbations during pregnancy.
22 Jul, 2022 | 11:09h | UTC
Retrospective cohort study | Impact of ethnicity on the accuracy of measurements of oxygen saturations.
21 Jul, 2022 | 13:15h | UTCRelated:
Racial Bias in Pulse Oximetry Measurement – New England Journal of Medicine
FDA issues alert on ‘limitations’ of pulse oximeters, without explicit mention of racial bias – STAT
Pulse Oximeter Accuracy and Limitations: FDA Safety Communication – U.S. Food & Drug Administration
RCT | Effect of Nintedanib on progression of systemic sclerosis-associated interstitial lung disease over 100 weeks.
21 Jul, 2022 | 13:03h | UTCCommentary: Durable Efficacy for Drug Preventing Lung Progression in Systemic Sclerosis — One-year results sustained over another 48 weeks – MedPage Today (free registration required)
RCT | Using a smartphone application maintains physical activity following pulmonary rehabilitation in patients with COPD.
21 Jul, 2022 | 12:45h | UTC
Review | New antibiotics for hospital-acquired pneumonia and ventilator-associated pneumonia.
20 Jul, 2022 | 11:44h | UTC
Review | The ABCDE approach to difficult weaning from venoarterial extracorporeal membrane oxygenation.
19 Jul, 2022 | 13:49h | UTC
RCT | Intranasal corticosteroids not beneficial for children with obstructive sleep apnea.
19 Jul, 2022 | 13:27h | UTCA trial of intranasal corticosteroids to treat the childhood obstructive sleep apnea syndrome – CHEST (link to abstract – $ for full-text)
Commentaries:
Intranasal corticosteroids not recommended for most children with OSA: study – Medical Dialogues
Commentary on Twitter
In children with obstructive sleep apnea syndrome, treatment with intranasal corticosteroids did not result in significant polysomnographic, neurobehavioral, and symptom changes compared to placebo, according to research in @journal_CHEST. https://t.co/e4bt4NMv5Z pic.twitter.com/FrIBdoMABf
— American Academy of Sleep Medicine (@AASMorg) July 11, 2022
Management of interstitial lung disease (ILD) in myositis syndromes: a practical guide for clinicians.
19 Jul, 2022 | 13:13h | UTC
Cohort Study | Reactogenicity of simultaneous COVID-19 mRNA booster and influenza vaccination.
18 Jul, 2022 | 11:34h | UTCCommentaries:
More (mostly mild) side effects when flu vaccine given with COVID booster – CIDRAP
Recent advances in the management of pulmonary hypertension with interstitial lung disease.
18 Jul, 2022 | 11:01h | UTC
Review | Imaging the acute respiratory distress syndrome: past, present and future.
15 Jul, 2022 | 13:05h | UTCImaging the acute respiratory distress syndrome: past, present and future – Intensive Care Medicine
Commentary on Twitter
Imaging #ARDS: past, present & future
➡️ physiopathology
➡️ management: PEEP/recruitment; inflation (& hyperinfation)
➡️ effects of proning on ventilation/perfusion
➡️ lung infammation
➡️ #COVID19
➡️ identifying complications
➡️ prognostication
& more!
? https://t.co/tEp50muK8J pic.twitter.com/GlME1vTePh— Intensive Care Medicine (@yourICM) July 14, 2022
RCT | Tixagevimab-cilgavimab for treatment of patients hospitalized with COVID-19.
15 Jul, 2022 | 13:02h | UTCCommentary: The potential of tixagevimab–cilgavimab for treating hospitalized COVID-19 patients – News Medical
Related:
Commentary on Twitter
In pts hospitalised w/ COVID-19 receiving remdesivir and other standard care, tixagevimab–cilgavimab did not improve time to sustained recovery but was safe and mortality was lower vs placebo
From the ACTIV-3–TICO Study Group https://t.co/zaaXBQYl5t pic.twitter.com/xe0tmbFrZ9
— The Lancet Respiratory Medicine (@LancetRespirMed) July 11, 2022
Review | Invasive respiratory fungal infections in COVID-19 critically ill patients.
15 Jul, 2022 | 12:58h | UTCInvasive Respiratory Fungal Infections in COVID-19 Critically Ill Patients – Journal of Fungi
A guide for managing patients with stage I NSCLC: deciding between lobectomy, segmentectomy, wedge, SBRT and ablation.
15 Jul, 2022 | 12:55h | UTCA guide for managing patients with stage I NSCLC: deciding between lobectomy, segmentectomy, wedge, SBRT and ablation – Journal of Thoracic Disease
Part 1 – A guide to decision-making
Part 2 – Systematic review of evidence regarding resection extent in generally healthy patients
Part 3 – Systematic review of evidence regarding surgery in compromised patients or specific tumors
Part 4 – Systematic review of evidence involving SBRT and ablation
M-A (mostly of observational studies) | Catheter-directed thrombolysis vs. systemic anticoagulation alone for submassive pulmonary embolism.
15 Jul, 2022 | 12:39h | UTC
Review | Strongyloides stercoralis.
15 Jul, 2022 | 12:23h | UTCStrongyloides stercoralis – Lung (if the link is paywalled, try this one)
Systematic Review | Anti‐IL‐5 therapies for asthma.
14 Jul, 2022 | 12:40h | UTCAnti‐IL‐5 therapies for asthma – Cochrane Library
M-A | Home oxygen for moderate hypoxemia in chronic obstructive pulmonary disease.
13 Jul, 2022 | 11:47h | UTCHome oxygen for moderate hypoxaemia in chronic obstructive pulmonary disease: a systematic review and meta-analysis – The Lancet Respiratory Medicine (link to abstract – $ for full-text)
Commentary on Twitter
Home oxygen probably makes little or no difference to 3-year mortality in pts with #COPD and moderate hypoxaemia
Systematic review & meta-analysis from Yves Lacasse & colleagues https://t.co/8wDrkEd1LH pic.twitter.com/UoOqW7hngT
— The Lancet Respiratory Medicine (@LancetRespirMed) July 11, 2022
AHA Science Advisory | Elucidating the clinical implications and pathophysiology of pulmonary hypertension in heart failure with preserved ejection fraction: a call to action.
13 Jul, 2022 | 11:40h | UTC
What cardiologists should know about sleep.
13 Jul, 2022 | 11:32h | UTCWhat cardiologists should know about sleep – European Heart Journal (free for a limited period)
RCT | Efficacy and safety of Elexacaftor/Tezacaftor/Ivacaftor in children 6 through 11 years of age with cystic fibrosis heterozygous for F508del and a minimal function mutation.
13 Jul, 2022 | 11:07h | UTCEfficacy and Safety of Elexacaftor/Tezacaftor/Ivacaftor in Children 6 Through 11 Years of Age with Cystic Fibrosis Heterozygous for F508del and a Minimal Function Mutation: A Phase 3B, Randomized, Placebo-Controlled Study – American Journal of Respiratory and Critical Care Medicine (link to abstract – $ for full-text)
New coronavirus mutant (BA.2.75) raises concerns in India and beyond.
12 Jul, 2022 | 12:59h | UTCNew coronavirus mutant raises concerns in India and beyond – Associated Press
Perspective | Why BA.5 feels different: the latest wave of infections is a test of our pandemic priorities.
12 Jul, 2022 | 13:03h | UTCWhy BA.5 Feels Different – The Atlantic
M-A | Accuracy of rapid point-of-care antigen-based diagnostics for SARS-CoV-2.
12 Jul, 2022 | 12:50h | UTCRelated:
Interpreting a lateral flow SARS-CoV-2 antigen test – The BMJ